Q&A: How can new drugs help weight loss resolutions stick?

Consumer interest in weight loss is high—three of the top five 2026 resolutions involve weight and diet—but historical adherence is poor (about 25% quit within a week, >50% by Feb. 1, and <10% succeed). A newly common class of GLP‑1 receptor agonists, including a pill approved this week and longer‑acting agents that persist 5–7 days, substantially suppress appetite and slow GI transit; traditional diet-and-exercise typically yields ~10% weight loss with 50–80% regain, while patients needing 20–30% reduction are unlikely to achieve that without pharmacotherapy. Clinicians emphasize personalized plans and that the goal is improved health and functionality rather than just weight numbers.

Analysis

Market structure: Clear winners are large GLP‑1 manufacturers (primary tickers: LLY, NVO) plus PBMs/retail pharmacies (CVS, WBA) that capture script flow; consumer brands tied to weight loss programs and gym memberships (WW, PLNT) are direct losers as recurring subscription/use declines. Pricing power will be strong initially because demand likely outstrips biologic manufacturing capacity; incumbents with scale and supply contracts will capture most early economic rent.

Competitive dynamics & supply/demand: Expect 6–18 month acute demand surge as eligibility and off‑label use expands—if only 5–10% of U.S. adults with obesity initiate therapy (~5–10M patients), that implies $5–30B incremental annual TAM at $1k–$3k/net patient price, concentrating upside on market leaders. Near term this supports higher equity multiples for LLY/NVO and increased PBM volumes; medium term (18–36 months) expect price compression as oral entrants and narrow‑formulary payor tactics emerge.

Risk assessment: Tail risks include regulatory safety signals, aggressive payer restrictions, and manufacturing bottlenecks; a single major safety or reimbursement reversal could cut peak sales 30–60% within 6–12 months. Hidden dependencies: high discontinuation rates produce churn, limiting lifetime value; catalysts to watch next 30–120 days are new approvals, CMS/payer coverage memos, and capacity expansion announcements.

Contrarian view: Consensus may overpay for perpetual high ASPs—historical parallel: PCSK9 uptake then formulary pushback. Mispricing opportunity: market leaders’ revenue growth is real but margin durability is uncertain; smaller oral‑GLP developers could become takeover targets rather than long‑term share winners.

Key Decisions for Investors

• Establish a 2–3% long position in Eli Lilly (LLY) over 6–12 months: use a funded call spread (buy 12‑month 15% OTM call, sell 12‑month 35% OTM call) to target ~30–40% upside while capping cost; add if CMS/payer coverage broadens in next 90 days.
• Establish a 1–2% long in Novo Nordisk (NVO) as a delta hedge to LLY exposure—prefer 9–18 month LEAP call calendar spread to benefit from near‑term ASPs but protect vs long‑run price compression.
• Initiate a 1% short in WW International (WW) or buy a 3‑6 month 15% OTM put spread sized to the long GLP‑1 exposure—expect subscriber attrition and FX/net‑sales headwinds within 3–9 months.
• Pair trade: long LLY (2%) / short WW (1%) to capture relative upside if uptake is branded‑concentrated; if a negative payer policy is announced within 60–120 days, close the long and widen the short to protect downside.